OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhibitors in fibrosis

Mechelen, Belgium and Warsaw, Poland, 5 November 2020, 22:15 CET – Galapagos NV (Euronext & NASDAQ: GLPG) and OncoArendi Therapeutics SA (WSE: OAT), announced that they have signed an exclusive collaboration and license agreement for the global development and commercialization of OncoArendi’s OATD-01. OATD-01 is a Phase 2-ready chitotriosidase/acidic mammalian chitinase (CHIT1/AMCase) inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and other diseases with a fibrotic component.   

Lung diseases like IPF are associated with an increased chitinase activity, which strongly correlates with disease stage, progression and prognosis. Chitinases (predominantly CHIT1) are involved in macrophage activation. Inhibition of chitinase activity translates into a potential therapeutic benefit, as shown in a range of preclinical models. OATD-01 has shown robust anti-fibrotic activity in multiple animal models, when compared with the standard of care.

meatnetadmOncoArendi and Galapagos enter into exclusive collaboration on chitinase inhibitors in fibrosis
Czytaj więcej

American Journal of Medicinal Chemistry distinguishes OncoArendi publication on OATD-01

A new publication about the discovery and preclinical characterization of OATD-01, authored by the scientists from OncoArendi Therapeutics, has just been accepted by the Journal of Medicinal Chemistry (J. Med. Chem). OATD-01 is a first-in-class chitinase inhibitor, which had recently completed Phase I studies and continues its development as a clinical candidate for the treatment of sarcoidosis, idiopathic pulmonary fibrosis (IPF), and possibly other fibrotic and inflammatory diseases.

Magda KućmaAmerican Journal of Medicinal Chemistry distinguishes OncoArendi publication on OATD-01
Czytaj więcej

OncoArendi Therapeutics expands the therapeutic potential of its Chitinase Platform

OncoArendi develops OATD-01 as a drug candidate for treatment of severe inflammatory and fibrotic diseases. Clinical trials in patients must be preceded by a number of preclinical safety studies, including GLP standard chronic toxicology. Such studies, outsourced to Charles River (USA), a leading global CRO (Contract Research Organization) have recently completed dosing. The 6 and 9 month period of administration of OATD-01 in rats and dogs (respectively) has just ended. A recovery phase of several weeks is currently ongoing. Preliminary reports of these studies are expected at the end of January 2021, while the final reports will be obtained in the second half of 2021. It should be emphasized that previously completed 17-week toxicology studies, also performed by Charles River, already enable Phase IIa studies in sarcoidosis patients to begin early next year.

Magda KućmaOncoArendi Therapeutics expands the therapeutic potential of its Chitinase Platform
Czytaj więcej

OncoArendi Therapeutics broadens its collaboration with VIB, a leading life science research institute in Europe, to investigate the role of chitinase family of proteins as potential therapeutic targets in COVID-19 patients

OncoArendi Therapeutics SA today signed an agreement with VIB, one of the world leading life science research institutes. The scope of this research collaboration focuses on the role of chitinase and chitinase-like-proteins (CLPs) in COVID-19 and subsequent complication. This collaboration can lead to identification of new drug candidates that can alleviate COVID-19 complications, such as lung fibrosis.

Magda KućmaOncoArendi Therapeutics broadens its collaboration with VIB, a leading life science research institute in Europe, to investigate the role of chitinase family of proteins as potential therapeutic targets in COVID-19 patients
Czytaj więcej

OncoArendi Therapeutics has received the final report from the phase Ib clinical trial of innovative drug candidate OATD-01

  •  the report confirms the OATD-01 safety profile which justifies further clinical development of this experimental drug
  • In Q1 of 2021 the company plans to file for an approval of the next phase clinical trial in sarcoidosis patients

OncoArendi Therapeutics S.A. (GPW: OAT) — a biotechnology company which specializes in discovery and development of new drugs will continue the clinical development of the OATD-01 molecule — an innovative small molecule chitinase inhibitor — in the treatment of severe pulmonary diseases such as sarcoidosis or idiopathic pulmonary fibrosis (IPF). OncoArendi Therapeutics is the first and so far only biotechnology company in the world, which conducts clinical trials of drug candidates targeting chitinase (first-in-class).

Magda KućmaOncoArendi Therapeutics has received the final report from the phase Ib clinical trial of innovative drug candidate OATD-01
Czytaj więcej

Dr. Zbigniew Zasłona joins OncoArendi Therapeutics as the new Director of the Biology Department. Dr Paweł Dobrzański, the current head of the Biology Department, will still be engaged in collaboration with OncoArendi as Senior Scientific Advisor on the company’s Scientific Advisory Board.

Dr. Zbigniew Zasłona, a biologist and scientist with impressive achievements in the area of pulmonary diseases (at Trinity College Dublin since 2015) has joined the research team of OncoArendi Therapeutics S.A. Prior to his collaboration with OncoArendi dr. Zasłona was a Senior Investigator at a biopharmaceutical company Sitryx, where he was responsible for studies on new therapeutic targets in the field of immunometabolism (development of anti-inflammatory medicines).

Magda KućmaDr. Zbigniew Zasłona joins OncoArendi Therapeutics as the new Director of the Biology Department. Dr Paweł Dobrzański, the current head of the Biology Department, will still be engaged in collaboration with OncoArendi as Senior Scientific Advisor on the company’s Scientific Advisory Board.
Czytaj więcej

Dr Timi Oshodi joined OncoArendi Therapeutics

OncoArendi Therapeutics – a biotechnology company specializing in the discovery, development and commercialization of innovative drugs, has hired Dr. Timi Oshodi as Director of Preclinical Development. Dr. Oshodi will be responsible for planning and implementing of preclinical safety and pharmacokinetic studies for molecules developed by the company.

Magda KućmaDr Timi Oshodi joined OncoArendi Therapeutics
Czytaj więcej

A new series of publications about the future prospects and development of Polish biotechnology sector was released by Technology Transfer and Entrepreneurship

A new series of publications about the future prospects and development of Polish biotechnology sector was released by Technology Transfer and Entrepreneurship, including case study of #OncoArendi Therapeutics authored by Marcin Szumowski

Magda KućmaA new series of publications about the future prospects and development of Polish biotechnology sector was released by Technology Transfer and Entrepreneurship
Czytaj więcej

OncoArendi Therapeutics has completed a Phase Ib clinical trial with an innovative small molecule experimental drug – OATD-01. Further analyses of the data from the study will lead to the final report and advancing to phase II clinical trials in patients

OncoArendi Therapeutics – a clinical stage biotechnology company specializing in the discovery and development of innovative small molecule drugs continues the clinical development of its first-in-class experimental drug candidate for treatment of sarcoidosis and idiopathic pulmonary fibrosis (IPF). OncoArendi Therapeutics is the first and thus far the only biotechnology company in the world conducting clinical research on new drugs blocking the activity of chitinase proteins.

OncoArendi Therapeutics announces the end of the clinical part of phase Ib trial (multiple ascending dose (MAD)) of the OATD-01 compound after confirming the tolerability of the tested doses and achieving the estimated pharmacodynamic effect. This was the second early phase clinical study after the successfully completed phase Ia “First in Human study” (single ascending dose – SAD).

Magda KućmaOncoArendi Therapeutics has completed a Phase Ib clinical trial with an innovative small molecule experimental drug – OATD-01. Further analyses of the data from the study will lead to the final report and advancing to phase II clinical trials in patients
Czytaj więcej

Drug Candidate OATD-01 may find use in treatment of pulmonary fibrosis in patients who have survived a new coronavirus infection (COVID-19)

  • Potential effectiveness of OATD-01 in the treatment of pulmonary fibrosis is based on a unique mechanism of inhibiting a new biological target – chitotriosidase 1 (CHIT1)
  • Linking COVID-19 infection to pulmonary fibrosis where CHIT1 plays a role will increase the value of OATD-01 and other chitinase inhibitors for potential partners
Magda KućmaDrug Candidate OATD-01 may find use in treatment of pulmonary fibrosis in patients who have survived a new coronavirus infection (COVID-19)
Czytaj więcej